Exploring the reactivity of flavonoid compounds with metal-associated amyloid-β species.

Metal ions associated with amyloid-β (Aβ) peptides have been suggested to be involved in the development of Alzheimer's disease (AD), but this remains unclear and controversial. Some attempts to rationally design or select small molecules with structural moieties for metal chelation and Aβ interaction (i.e., bifunctionality) have been made to gain a better understanding of the hypothesis. In order to contribute to these efforts, four synthetic flavonoid derivatives FL1-FL4 were rationally selected according to the principles of bifunctionality and their abilities to chelate metal ions, interact with Aβ, inhibit metal-induced Aβ aggregation, scavenge radicals, and regulate the formation of reactive oxygen species (ROS) were studied using physical methods and biological assays. The compounds FL1-FL3 were able to chelate metal ions, but showed limited solubility in aqueous buffered solutions. In the case of FL4, which was most compatible with aqueous conditions, its binding affinities for Cu(2+) and Zn(2+) (nM and μM, respectively) were obtained through solution speciation studies. The direct interaction between FL4 and Aβ monomer was weak, which was monitored by NMR spectroscopy and mass spectrometry. Employing FL1-FL4, no noticeable inhibitory effect on metal-mediated Aβ aggregation was observed. Among FL1-FL4, FL3, having 3-OH, 4-oxo, and 4'-N(CH(3))(2) groups, exhibited similar antioxidant activity to the vitamin E analogue, Trolox, and ca. 60% reduction in the amount of hydrogen peroxide (H(2)O(2)) generated by Cu(2+)-Aβ in the presence of dioxygen (O(2)) and a reducing agent. Overall, the studies here suggest that although four flavonoid molecules were selected based on expected bifunctionality, their properties and metal-Aβ reactivity were varied depending on the structure differences, demonstrating that bifunctionality must be well tuned to afford desirable reactivity.

[1]  M. Lim,et al.  Metal-associated amyloid-β species in Alzheimer's disease. , 2012, Current opinion in chemical biology.

[2]  Ayyalusamy Ramamoorthy,et al.  Misfolded proteins in Alzheimer's disease and type II diabetes. , 2012, Chemical Society reviews.

[3]  A. Ramamoorthy,et al.  Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species. , 2011, Inorganic chemistry.

[4]  C. Masters,et al.  The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity , 2011, Journal of neurochemistry.

[5]  Alaina S. DeToma,et al.  Myricetin: A Naturally Occurring Regulator of Metal‐Induced Amyloid‐β Aggregation and Neurotoxicity , 2011, Chembiochem : a European journal of chemical biology.

[6]  Changlin Liu,et al.  The chelation targeting metal-Aβ40 aggregates may lead to formation of Aβ40 oligomers. , 2011, Dalton transactions.

[7]  T. Storr,et al.  N-Aryl-substituted 3-(β-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy , 2011 .

[8]  M. Lim,et al.  Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation. , 2011, Metallomics : integrated biometal science.

[9]  G. Perry,et al.  Role of metal dyshomeostasis in Alzheimer's disease. , 2011, Metallomics : integrated biometal science.

[10]  Ann Tiiman,et al.  Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. , 2011, Metallomics : integrated biometal science.

[11]  J. Shearer,et al.  Cu K-edge X-ray absorption spectroscopy reveals differential copper coordination within amyloid-β oligomers compared to amyloid-β monomers. , 2010, Chemical communications.

[12]  R. Nanga,et al.  Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity , 2010, Proceedings of the National Academy of Sciences.

[13]  H. Tamura,et al.  An effective synthesis of 5,4'-disubstituted flavones via a cesium enolate assisted intramolecular ipso-substitution reaction. , 2010, Chemical & pharmaceutical bulletin.

[14]  K. Blennow,et al.  PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. , 2010, Journal of Alzheimer's disease : JAD.

[15]  K. Lee,et al.  Naturally occurring phytochemicals for the prevention of Alzheimer’s disease , 2010, Journal of neurochemistry.

[16]  K. Franz,et al.  Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease. , 2010, Dalton transactions.

[17]  Xinyu Jiang,et al.  Effect of Zinc (II) on the interactions of bovine serum albumin with flavonols bearing different number of hydroxyl substituent on B-ring. , 2010, Journal of inorganic biochemistry.

[18]  Peter Faller,et al.  Copper and Zinc Binding to Amyloid‐β: Coordination, Dynamics, Aggregation, Reactivity and Metal‐Ion Transfer , 2009, Chembiochem : a European journal of chemical biology.

[19]  A. Ramamoorthy,et al.  Small molecule modulators of copper-induced Abeta aggregation. , 2009, Journal of the American Chemical Society.

[20]  P. Faller,et al.  Abeta-mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease. , 2009, Biochimie.

[21]  A. Rauk The chemistry of Alzheimer's disease. , 2009, Chemical Society reviews.

[22]  C. Orvig,et al.  Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. , 2009, Chemical reviews.

[23]  H. Jacobsen,et al.  Alzheimer's disease: from pathology to therapeutic approaches. , 2009, Angewandte Chemie.

[24]  H. Saji,et al.  18F-labeled flavones for in vivo imaging of beta-amyloid plaques in Alzheimer's brains. , 2009, Bioorganic & medicinal chemistry.

[25]  P. Faller,et al.  Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. , 2009, Dalton transactions.

[26]  J. Vidal-Gancedo,et al.  Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. , 2009, Journal of the American Chemical Society.

[27]  P. Chou,et al.  Dual excited-state intramolecular proton transfer reaction in 3-hydroxy-2-(pyridin-2-yl)-4H-chromen-4-one. , 2009, The journal of physical chemistry. A.

[28]  A. Bush,et al.  Sequestration of Copper from β-Amyloid Promotes Selective Lysis by Cyclen-Hybrid Cleavage Agents* , 2008, Journal of Biological Chemistry.

[29]  K. Karlin,et al.  Structural studies of copper(I) complexes of amyloid-beta peptide fragments: formation of two-coordinate bis(histidine) complexes. , 2008, Angewandte Chemie.

[30]  C. Masters,et al.  Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ , 2008, Neuron.

[31]  Ashley I. Bush,et al.  Therapeutics for Alzheimer’s disease based on the metal hypothesis , 2008, Neurotherapeutics.

[32]  S. Mazères,et al.  Thioflavin Derivatives as Markers for Amyloid‐β Fibrils: Insights into Structural Features Important for High‐Affinity Binding , 2008, ChemMedChem.

[33]  J. Danielsson,et al.  Positioning of the Alzheimer Aβ(1–40) peptide in SDS micelles using NMR and paramagnetic probes , 2007, Journal of biomolecular NMR.

[34]  H. Schugar,et al.  Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. , 2007, Angewandte Chemie.

[35]  Kenjiro Ono,et al.  The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. , 2007, Biochemistry.

[36]  B. Meunier,et al.  Influence of chelators and iron ions on the production and degradation of H2O2 by beta-amyloid-copper complexes. , 2006, Journal of inorganic biochemistry.

[37]  H. Kozłowski,et al.  Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). , 2006, Chemical reviews.

[38]  Ehud Gazit,et al.  Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism , 2006, Chemical biology & drug design.

[39]  Masahiro Ono,et al.  Radioiodinated Flavones for in Vivo Imaging of β-Amyloid Plaques in the Brain , 2005 .

[40]  A. Bush,et al.  The neurobiology of zinc in health and disease , 2005, Nature Reviews Neuroscience.

[41]  Xudong Huang,et al.  Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis , 2004, Experimental Gerontology.

[42]  A. Takashima,et al.  Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease , 2003, Journal of neurochemistry.

[43]  Xudong Huang,et al.  Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). , 2002, The Journal of biological chemistry.

[44]  D. Selkoe,et al.  The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics , 2002, Science.

[45]  Rui M. Rocha,et al.  Interactions of Flavonoids with Iron and Copper Ions: A Mechanism for their Antioxidant Activity , 2002, Free radical research.

[46]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[47]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[48]  M B Katan,et al.  Dietary flavonoids: intake, health effects and bioavailability. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[49]  C. Rice-Evans,et al.  Antioxidant activity applying an improved ABTS radical cation decolorization assay. , 1999, Free radical biology & medicine.

[50]  P. Gans,et al.  Hyperquad simulation and speciation (HySS): a utility program for the investigation of equilibria involving soluble and partially soluble species , 1999 .

[51]  D. Craik,et al.  Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? , 1998, Biochemistry.

[52]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[53]  D. S. Garrett,et al.  Identification by NMR of the binding surface for the histidine-containing phosphocarrier protein HPr on the N-terminal domain of enzyme I of the Escherichia coli phosphotransferase system. , 1997, Biochemistry.

[54]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[55]  S. Grzesiek,et al.  The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase , 1996, Nature Structural Biology.

[56]  D. F. Kelley,et al.  Proton transfer dynamics in substituted 3‐hydroxyflavones: Solvent polarization effects , 1993 .

[57]  W. Jahnke,et al.  Chemical shift as a probe of molecular interfaces: NMR studies of DNA binding by the three amino-terminal zinc finger domains from transcription factor IIIA , 1998, Journal of biomolecular NMR.

[58]  C. Rice-Evans,et al.  Structure-antioxidant activity relationships of flavonoids and phenolic acids. , 1996, Free radical biology & medicine.